Lanvis

Tioguanine, the active ingredient in Lanvis, is an antimetabolite (purine analog) presented as an oral formulation for oral use. It is employed in the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia in patients requiring cytotoxic therapy.

GNH USA supplies Lanvis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanvis is an antimetabolite used in hematologic malignancies that affect rapidly dividing blood cells.

Acute lymphoblastic leukemia: helps achieve remission by targeting proliferating lymphoblasts. Chronic myeloid leukemia: contributes to disease control as part of maintenance therapy.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Myelosuppression (low blood counts) - Fatigue - Alopecia (hair loss) - Mucositis (mouth sores) - Diarrhea

Serious or Rare Side Effects: - Severe bone marrow failure - Hepatic toxicity - Secondary malignancies - Life‑threatening infections - Severe hypersensitivity reactions - Pulmonary fibrosis

Safety considerations should be observed before and during therapy.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess liver function: check hepatic enzymes prior to initiation. Avoid use in severe infection: defer treatment until infection is controlled. Use caution in renal impairment: adjust dosing as needed. Adjust dose in hepatic dysfunction: follow clinical guidelines. Store at room temperature: keep in original packaging, protect from moisture and light.

Potential drug‑drug interactions may affect efficacy or safety.

Major Interactions (Avoid): - Azathioprine: increased myelosuppression risk. - Allopurinol: heightened toxicity of Tioguanine. - Methotrexate: enhanced bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR. - NSAIDs: increased gastrointestinal toxicity. - Anticonvulsants (enzyme inducers): may reduce Tioguanine effectiveness.